5-Fluorouracil Therapeutic Cheat Sheet
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The …
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The … 
Hyperhidrosis affects approximately 4.8% of the U.S. population1 and causes patients significant psychosocial distress. Patients are looking to maximize non-invasive treatment options while avoiding systemic side effects. We continue our series, Therapeutic Cheat Sheet, with a closer look at glycopyrronium tosylate cloths.
[caption id="attachment_11862" align="alignleft" width="1934"] Click ima … 
When standard treatment options fail and corticosteroids are not a long-term option, dermatologists often have to look back to their tool-kit and pull out the “big guns.” Mycophenolate mofetil has emerged as a promising immunosuppressive agent for severe immune-mediated and inflammatory dermatologic disease. We continue our series, Therapeutic Cheat Sheet, with a closer look at mycophenolate m … 
In this month’s installment of our Therapeutic Cheat Sheet Series, we will review the topical immunomodulatory agent imiquimod. Originally approved for the treatment of external genital warts, FDA approval has expanded to include use as field therapy for actinic keratoses as well as treatment of superficial basal cell carcinomas. Here’s what you need to know about imiquimod.
[caption id=" … 
With the advent of biologics, patients with moderate-to-severe plaque psoriasis have experienced increased control of disease and improved quality of life. Tumor necrosis factor (TNF) inhibitors are some of the earliest biologics prescribed for psoriasis, psoriatic arthritis and, more recently, hidradenitis suppurativa. In this month’s installment of Therapeutic Cheat Sheets, we discuss TNF inhi … 